JP5406040B2 - 医薬使用のためのリパーゼ変異体 - Google Patents

医薬使用のためのリパーゼ変異体 Download PDF

Info

Publication number
JP5406040B2
JP5406040B2 JP2009543078A JP2009543078A JP5406040B2 JP 5406040 B2 JP5406040 B2 JP 5406040B2 JP 2009543078 A JP2009543078 A JP 2009543078A JP 2009543078 A JP2009543078 A JP 2009543078A JP 5406040 B2 JP5406040 B2 JP 5406040B2
Authority
JP
Japan
Prior art keywords
lipase
seq
enzyme
amino acids
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009543078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512795A5 (OSRAM
JP2010512795A (ja
Inventor
スベンセン,アラン
スクヨエット,ミシェル
ヤバー,デビー
レーマン ヒュリング クリステンセン,ラーズ
エスキルセン ラーセン,シグネ
ルンディン,ニーナ
ランサ,マイケル
コリン グレゴリー,ピーター
Original Assignee
ノボザイムス アクティーゼルスカブ
ノボザイムス,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボザイムス アクティーゼルスカブ, ノボザイムス,インコーポレイティド filed Critical ノボザイムス アクティーゼルスカブ
Publication of JP2010512795A publication Critical patent/JP2010512795A/ja
Publication of JP2010512795A5 publication Critical patent/JP2010512795A5/ja
Application granted granted Critical
Publication of JP5406040B2 publication Critical patent/JP5406040B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • C12N9/20Triglyceride splitting, e.g. by means of lipase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003Triacylglycerol lipase (3.1.1.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2009543078A 2006-12-21 2007-12-12 医薬使用のためのリパーゼ変異体 Active JP5406040B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87119606P 2006-12-21 2006-12-21
US60/871,196 2006-12-21
PCT/US2007/087168 WO2008079685A2 (en) 2006-12-21 2007-12-12 Lipase variants for pharmaceutical use

Publications (3)

Publication Number Publication Date
JP2010512795A JP2010512795A (ja) 2010-04-30
JP2010512795A5 JP2010512795A5 (OSRAM) 2011-02-03
JP5406040B2 true JP5406040B2 (ja) 2014-02-05

Family

ID=38043020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009543078A Active JP5406040B2 (ja) 2006-12-21 2007-12-12 医薬使用のためのリパーゼ変異体

Country Status (16)

Country Link
US (3) US8273348B2 (OSRAM)
EP (6) EP2455462B1 (OSRAM)
JP (1) JP5406040B2 (OSRAM)
KR (1) KR20090101930A (OSRAM)
CN (2) CN101743308B (OSRAM)
AR (1) AR064494A1 (OSRAM)
AU (1) AU2007337150A1 (OSRAM)
BR (1) BRPI0721103A2 (OSRAM)
CA (3) CA3081308C (OSRAM)
IL (1) IL198893A0 (OSRAM)
MX (1) MX2009006597A (OSRAM)
NO (1) NO20092729L (OSRAM)
RU (1) RU2009128067A (OSRAM)
TW (1) TW200829698A (OSRAM)
WO (1) WO2008079685A2 (OSRAM)
ZA (1) ZA200903598B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005092370A1 (en) 2004-03-22 2005-10-06 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
ES2597381T3 (es) 2005-07-29 2017-01-18 Abbott Laboratories Gmbh Procesos para la fabricación de polvo de pancreatina con bajo contenido en virus
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2455462B1 (en) * 2006-12-21 2016-03-16 Novozymes A/S Lipase variants for pharmaceutical use
US8637101B2 (en) 2008-02-29 2014-01-28 Dsm Ip Assets B.V. Lipases with high specificity towards short chain fatty acids and uses thereof
WO2009111258A2 (en) * 2008-02-29 2009-09-11 The Procter & Gamble Company Detergent composition comprising lipase
MX337307B (es) * 2008-02-29 2016-02-25 Novozymes As Variante de enzima lipolitica con estabilidad mejorada y polinucleotidos que codifican para la misma.
EP2510092A1 (en) 2009-12-09 2012-10-17 The Procter & Gamble Company Fabric and home care products
DK2734633T3 (da) 2011-07-22 2019-06-11 Novozymes North America Inc Fremgangsmåder til forbehandling af celluloseholdigt materiale og forbedring af hydrolyse deraf
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
ES2887576T3 (es) * 2011-12-29 2021-12-23 Novozymes As Composiciones detergentes con variantes de lipasa
MX391773B (es) 2012-02-03 2025-03-21 Novozymes As Variantes de lipasa y polinucleótidos que las codifican.
US9909109B2 (en) 2012-04-02 2018-03-06 Novozymes A/S Lipase variants and polynucleotides encoding same
HK1209785A1 (en) * 2012-10-12 2016-04-08 Danisco Us Inc. Compositions and methods comprising a lipolytic enzyme variant
RU2020101263A (ru) * 2013-05-14 2020-02-17 Новозимс А/С Моющие композиции
MX371497B (es) * 2013-07-19 2020-01-31 Danisco Us Inc Composiciones y metodos que comprenden una variante de enzima lipolitica.
US10287562B2 (en) * 2014-11-20 2019-05-14 Novoszymes A/S Alicyclobacillus variants and polynucleotides encoding same
WO2016087401A1 (en) * 2014-12-05 2016-06-09 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2016091870A1 (en) * 2014-12-09 2016-06-16 Novozymes A/S Lipase variants and polynucleotides encoding same
WO2016164596A2 (en) 2015-04-07 2016-10-13 Novozymes A/S Methods for selecting enzymes having lipase activity
WO2017001673A1 (en) * 2015-07-01 2017-01-05 Novozymes A/S Methods of reducing odor
CN107995922B (zh) * 2015-07-03 2021-12-28 诺维信公司 在亚硫酸盐的存在下具有改进的稳定性的洗涤剂组合物
WO2018015295A1 (en) * 2016-07-18 2018-01-25 Novozymes A/S Lipase variants, polynucleotides encoding same and the use thereof
EP3575398A4 (en) * 2017-01-30 2020-11-11 Nippon Medical School Foundation ADENO-ASSOCIATED VIRUS (AAV) CAPSIDE PROTEIN MUTANT
CA3073362A1 (en) * 2017-09-27 2019-04-04 Novozymes A/S Lipase variants and microcapsule compositions comprising such lipase variants
MX2020003779A (es) * 2017-09-27 2020-08-03 Procter & Gamble Composiciones detergentes que comprenden lipasas.
US20210071156A1 (en) * 2018-02-08 2021-03-11 Novozymes A/S Lipase Variants and Compositions Thereof
WO2020037100A1 (en) * 2018-08-16 2020-02-20 Isolere Bio, Inc. Genetically encoded polypeptide for affinity capture and purification of biologics
CN111334369B (zh) * 2020-03-11 2022-10-21 陕西科技大学 一种酶法制备卵磷脂型pufa的方法
EP4172325A1 (en) * 2020-06-24 2023-05-03 Cilian AG New lipase enzyme
BR112023008326A2 (pt) * 2020-10-29 2023-12-12 Novozymes As Variantes de lipase e composições compreendendo tais variantes de lipase
CN113846074B (zh) * 2021-10-20 2022-10-21 南京林业大学 一种疏棉状嗜热丝孢菌脂肪酶突变体g91c及其应用
EP4525615A2 (en) 2022-05-14 2025-03-26 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections
EP4544015A2 (en) * 2022-06-24 2025-04-30 Novozymes A/S Lipase variants and compositions comprising such lipase variants

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173590D0 (da) 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5869438A (en) 1990-09-13 1999-02-09 Novo Nordisk A/S Lipase variants
DK46693D0 (OSRAM) * 1993-04-23 1993-04-23 Novo Nordisk As
JP3469234B2 (ja) * 1990-09-13 2003-11-25 ノボザイムス アクティーゼルスカブ リパーゼ変異体
WO1992010755A1 (en) 1990-12-05 1992-06-25 Novo Nordisk A/S Proteins with changed epitopes and methods for the production thereof
ATE169678T1 (de) 1991-05-01 1998-08-15 Novo Nordisk As Stabilisierte enzyme
DK39693D0 (da) 1993-04-02 1993-04-02 Novo Nordisk As Enzym
EP0722491A1 (en) 1993-10-04 1996-07-24 Novo Nordisk A/S An enzyme preparation comprising a modified enzyme
EP0746618B1 (en) 1994-02-22 2002-08-21 Novozymes A/S A method of preparing a variant of a lipolytic enzyme
EP0793726A1 (en) 1994-11-24 1997-09-10 Novo Nordisk A/S A process for producing polypeptides with reduced allergenicity
MX9704137A (es) 1994-12-07 1997-09-30 Novo Nordisk As Polipeptidos de alergenicidad reducida.
ES2169219T5 (es) 1995-01-26 2009-09-01 Novozymes A/S Aditivos alimenticios para animales que comprenden xilanasa.
DE69633825T2 (de) 1995-07-14 2005-11-10 Novozymes A/S Modifiziertes enzym mit lipolytischer aktivität
US6495357B1 (en) * 1995-07-14 2002-12-17 Novozyme A/S Lipolytic enzymes
DE69632538T2 (de) 1995-08-11 2005-05-19 Novozymes A/S Neuartige lipolytische enzyme
JP2002510963A (ja) 1997-01-10 2002-04-09 ノボザイムス アクティーゼルスカブ スキンケア用酵素修飾体
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
ATE375387T1 (de) 1997-06-25 2007-10-15 Novozymes As Modifiziertes polypeptid
ATE328070T1 (de) * 1998-02-17 2006-06-15 Novozymes As Lipasevariante
AU3247699A (en) 1998-02-17 1999-09-06 Novo Nordisk A/S Lipase variant
EP1121424A1 (en) 1998-10-13 2001-08-08 Novozymes A/S A modified polypeptide with reduced immune response
DE69938435D1 (de) 1998-10-30 2008-05-08 Novozymes As Niedrigallergene Proteinvarianten
ES2289824T3 (es) * 1998-10-30 2008-02-01 Novozymes A/S Proteinas glicosiladas con alergenicidad reducida.
NZ511340A (en) 1998-11-27 2003-07-25 Novozymes As Lipolytic enzyme variants
US7312062B2 (en) * 1998-11-27 2007-12-25 Novozymes A/S Lipolytic enzyme variants
CA2367355C (en) 1999-03-17 2012-06-05 Solvay Pharmaceuticals Gmbh Medicinal product for the treatment of diabetes
EP1171581A1 (en) 1999-03-31 2002-01-16 Novozymes A/S Lipase variant
EP2278000A1 (en) * 1999-03-31 2011-01-26 Novozymes A/S Lipase variant
CA2395343C (en) 2000-02-08 2009-06-30 F. Hoffmann-La Roche Ag Use of acid-stable proteases in animal feed
AU2001254623A1 (en) * 2000-04-28 2001-11-12 Novozymes A/S Production and use of protein variants having modified immunogenicity
AU2002219020B2 (en) * 2001-01-10 2007-05-24 Novozymes A/S Thermostable lipolytic enzyme variant
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
ATE443759T1 (de) 2001-02-07 2009-10-15 Novozymes As Lipasevarianten
EP1468084A1 (en) 2002-01-16 2004-10-20 Novozymes A/S Lipolytic enzyme variants and method for their production
WO2004069872A1 (en) 2003-02-06 2004-08-19 Novozymes A/S Human heavy chain antibody expression in filamentous fungi
WO2004099400A2 (en) 2003-05-09 2004-11-18 Novozymes A/S Variant lipolytic ensymes
WO2004111216A2 (en) 2003-06-19 2004-12-23 Novozymes A/S Phospholipase variants
EP1639107B1 (en) 2003-06-19 2013-08-14 Novozymes A/S Improved proteases and methods for producing them
EP1711529A1 (en) 2004-01-21 2006-10-18 Novozymes A/S Production of a monoclonal antibody in a heterokaryon fungus or in a fungal host cell
WO2005092370A1 (en) 2004-03-22 2005-10-06 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
DK1809320T3 (da) 2004-10-14 2010-11-15 Cystic Fibrosis Foundation The Præparater indeholdende lipase, protease og amylase til behandling af pankreatisk insufficiens
EP1851311A2 (en) 2005-02-10 2007-11-07 Novozymes A/S Enzymatic enantioselective ester or amide hydrolysis or synthesis
US8017351B2 (en) 2005-06-24 2011-09-13 Novozymes A/S Amylases for pharmaceutical use
MX2007015472A (es) 2005-06-24 2008-04-17 Novozymes As Lipasas para uso farmaceutico.
BRPI0611936A2 (pt) 2005-06-24 2011-02-22 Solvay Pharm Gmbh protease, uso de uma protease, composição farmacêutica, e, método para o tratamento de doença
WO2007080197A2 (en) * 2006-01-16 2007-07-19 Novozymes A/S Immobilised enzymes
DK1979477T3 (en) * 2006-01-23 2017-06-26 Novozymes As lipase variants
AR059154A1 (es) * 2006-01-23 2008-03-12 Procter & Gamble Una composicion que comprende una lipasa y un catalizador de blanqueador
EP2455462B1 (en) * 2006-12-21 2016-03-16 Novozymes A/S Lipase variants for pharmaceutical use

Also Published As

Publication number Publication date
RU2009128067A (ru) 2011-01-27
KR20090101930A (ko) 2009-09-29
IL198893A0 (en) 2010-02-17
US20150209414A1 (en) 2015-07-30
EP2455459A3 (en) 2013-04-24
CA3081308A1 (en) 2008-07-03
CA2961041C (en) 2020-07-14
CN101743308B (zh) 2015-09-16
US20120308543A1 (en) 2012-12-06
US20100034797A1 (en) 2010-02-11
CA2670643A1 (en) 2008-07-03
CA2961041A1 (en) 2008-07-03
US9539311B2 (en) 2017-01-10
US8273348B2 (en) 2012-09-25
AR064494A1 (es) 2009-04-08
CN105112386A (zh) 2015-12-02
NO20092729L (no) 2009-09-18
EP2455461B1 (en) 2016-03-16
AU2007337150A1 (en) 2008-07-03
MX2009006597A (es) 2009-07-02
ZA200903598B (en) 2010-04-28
EP2455459A2 (en) 2012-05-23
EP2455461A3 (en) 2013-05-29
BRPI0721103A2 (pt) 2014-03-04
EP2455460A3 (en) 2012-12-26
CN101743308A (zh) 2010-06-16
WO2008079685A3 (en) 2008-11-06
EP2455462B1 (en) 2016-03-16
TW200829698A (en) 2008-07-16
EP2455459B1 (en) 2016-03-16
EP2455462A3 (en) 2013-05-29
CA3081308C (en) 2024-02-20
EP2099907A2 (en) 2009-09-16
EP2455461A2 (en) 2012-05-23
EP2261328A1 (en) 2010-12-15
US9029115B2 (en) 2015-05-12
EP2261328B1 (en) 2013-11-20
EP2455462A2 (en) 2012-05-23
CA2670643C (en) 2017-04-25
JP2010512795A (ja) 2010-04-30
WO2008079685A2 (en) 2008-07-03
EP2455460A2 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
JP5406040B2 (ja) 医薬使用のためのリパーゼ変異体
US20090047266A1 (en) Lipases for Pharmaceutical Use
JP2008546396A (ja) 薬学的に使用するためのアミラーゼ
US8455235B2 (en) Protease variants for pharmaceutical use
AU2013203500B2 (en) Lipase variants for pharmaceutical use
AU2013200626B2 (en) Lipase variants for pharmaceutical use
HK1141553A (en) Lipase variants for pharmaceutical use
HK1113174A (en) Lipases for pharmaceutical use
HK1145697A (en) Protease variants for pharmaceutical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101210

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20111219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130717

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131031

R150 Certificate of patent or registration of utility model

Ref document number: 5406040

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250